Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation

Jared T. Hammill; Deepak Bhasin; Daniel C. Scott; Jaeki Min; Yizhe Chen; Yan Lu; Lei Yang; Ho Shin Kim; Michele C. Connelly; Courtney Hammill; Gloria Holbrook; Cynthia Jeffries; Bhuvanesh Singh; Brenda A. Schulman; R. Kiplin Guy

doi:10.1021/acs.jmedchem.7b01282

Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation

Jared T. Hammill, Deepak Bhasin, Daniel C. Scott, Jaeki Min, Yizhe Chen, Yan Lu, Lei Yang, Ho Shin Kim, Michele C. Connelly, Courtney Hammill, Gloria Holbrook, Cynthia Jeffries, Bhuvanesh Singh, Brenda A. Schulman, R. Kiplin Guy

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

We previously reported the discovery, validation, and structure-activity relationships of a series of piperidinyl ureas that potently inhibit the DCN1-UBE2M interaction. We demonstrated that compound 7 inhibits both the DCN1-UBE2M protein-protein interaction and DCN1-mediated cullin neddylation in biochemical assays and reduces levels of steady-state cullin neddylation in a squamous carcinoma cell line harboring DCN1 amplification. Although compound 7 exhibits good solubility and permeability, it is rapidly metabolized in microsomal models (CL _int = 170 mL/min/kg). This work lays out the discovery of an orally bioavailable analogue, NAcM-OPT (67). Compound 67 retains the favorable biochemical and cellular activity of compound 7 but is significantly more stable both in vitro and in vivo. Compound 67 is orally bioavailable, well tolerated in mice, and currently used to study the effects of acute pharmacologic inhibition of the DCN1-UBE2M interaction on the NEDD8/CUL pathway.

Original language	English
Pages (from-to)	2694-2706
Number of pages	13
Journal	Journal of Medicinal Chemistry
Volume	61
Issue number	7
DOIs	https://doi.org/10.1021/acs.jmedchem.7b01282
State	Published - Apr 12 2018

Bibliographical note

Funding Information:
We acknowledge the High Throughput Biosciences Center, Medicinal Chemistry Center, Compound Management, and High Throughput Analytical Chemistry Centers in Chemical Biology and Therapeutics, Hartwell Center, and Veterinary pathology cores of St. Jude Children’s Research Hospital for use of their personnel and facilities. This study was funded through B.A.S., HHMI, and NIH R37GM069530, P30CA021765; J.T.H., NIH F32GM113310; American Syrian Lebanese Associated Charities, and St Jude Children’s Research Hospital.

Publisher Copyright:
© 2018 American Chemical Society.

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1021/acs.jmedchem.7b01282

Cite this

Hammill, J. T., Bhasin, D., Scott, D. C., Min, J., Chen, Y., Lu, Y., Yang, L., Kim, H. S., Connelly, M. C., Hammill, C., Holbrook, G., Jeffries, C., Singh, B., Schulman, B. A., & Guy, R. K. (2018). Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. Journal of Medicinal Chemistry, 61(7), 2694-2706. https://doi.org/10.1021/acs.jmedchem.7b01282

@article{b17ed95f61954793bdb86c2802a304a6,

title = "Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation",

abstract = " We previously reported the discovery, validation, and structure-activity relationships of a series of piperidinyl ureas that potently inhibit the DCN1-UBE2M interaction. We demonstrated that compound 7 inhibits both the DCN1-UBE2M protein-protein interaction and DCN1-mediated cullin neddylation in biochemical assays and reduces levels of steady-state cullin neddylation in a squamous carcinoma cell line harboring DCN1 amplification. Although compound 7 exhibits good solubility and permeability, it is rapidly metabolized in microsomal models (CL int = 170 mL/min/kg). This work lays out the discovery of an orally bioavailable analogue, NAcM-OPT (67). Compound 67 retains the favorable biochemical and cellular activity of compound 7 but is significantly more stable both in vitro and in vivo. Compound 67 is orally bioavailable, well tolerated in mice, and currently used to study the effects of acute pharmacologic inhibition of the DCN1-UBE2M interaction on the NEDD8/CUL pathway. ",

author = "Hammill, {Jared T.} and Deepak Bhasin and Scott, {Daniel C.} and Jaeki Min and Yizhe Chen and Yan Lu and Lei Yang and Kim, {Ho Shin} and Connelly, {Michele C.} and Courtney Hammill and Gloria Holbrook and Cynthia Jeffries and Bhuvanesh Singh and Schulman, {Brenda A.} and Guy, {R. Kiplin}",

note = "Funding Information: We acknowledge the High Throughput Biosciences Center, Medicinal Chemistry Center, Compound Management, and High Throughput Analytical Chemistry Centers in Chemical Biology and Therapeutics, Hartwell Center, and Veterinary pathology cores of St. Jude Children{\textquoteright}s Research Hospital for use of their personnel and facilities. This study was funded through B.A.S., HHMI, and NIH R37GM069530, P30CA021765; J.T.H., NIH F32GM113310; American Syrian Lebanese Associated Charities, and St Jude Children{\textquoteright}s Research Hospital. Publisher Copyright: {\textcopyright} 2018 American Chemical Society.",

year = "2018",

month = apr,

day = "12",

doi = "10.1021/acs.jmedchem.7b01282",

language = "English",

volume = "61",

pages = "2694--2706",

number = "7",

}

Hammill, JT, Bhasin, D, Scott, DC, Min, J, Chen, Y, Lu, Y, Yang, L, Kim, HS, Connelly, MC, Hammill, C, Holbrook, G, Jeffries, C, Singh, B, Schulman, BA & Guy, RK 2018, 'Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation', Journal of Medicinal Chemistry, vol. 61, no. 7, pp. 2694-2706. https://doi.org/10.1021/acs.jmedchem.7b01282

TY - JOUR

T1 - Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation

AU - Hammill, Jared T.

AU - Bhasin, Deepak

AU - Scott, Daniel C.

AU - Min, Jaeki

AU - Chen, Yizhe

AU - Lu, Yan

AU - Yang, Lei

AU - Kim, Ho Shin

AU - Connelly, Michele C.

AU - Hammill, Courtney

AU - Holbrook, Gloria

AU - Jeffries, Cynthia

AU - Singh, Bhuvanesh

AU - Schulman, Brenda A.

AU - Guy, R. Kiplin

N1 - Funding Information: We acknowledge the High Throughput Biosciences Center, Medicinal Chemistry Center, Compound Management, and High Throughput Analytical Chemistry Centers in Chemical Biology and Therapeutics, Hartwell Center, and Veterinary pathology cores of St. Jude Children’s Research Hospital for use of their personnel and facilities. This study was funded through B.A.S., HHMI, and NIH R37GM069530, P30CA021765; J.T.H., NIH F32GM113310; American Syrian Lebanese Associated Charities, and St Jude Children’s Research Hospital. Publisher Copyright: © 2018 American Chemical Society.

PY - 2018/4/12

Y1 - 2018/4/12

N2 - We previously reported the discovery, validation, and structure-activity relationships of a series of piperidinyl ureas that potently inhibit the DCN1-UBE2M interaction. We demonstrated that compound 7 inhibits both the DCN1-UBE2M protein-protein interaction and DCN1-mediated cullin neddylation in biochemical assays and reduces levels of steady-state cullin neddylation in a squamous carcinoma cell line harboring DCN1 amplification. Although compound 7 exhibits good solubility and permeability, it is rapidly metabolized in microsomal models (CL int = 170 mL/min/kg). This work lays out the discovery of an orally bioavailable analogue, NAcM-OPT (67). Compound 67 retains the favorable biochemical and cellular activity of compound 7 but is significantly more stable both in vitro and in vivo. Compound 67 is orally bioavailable, well tolerated in mice, and currently used to study the effects of acute pharmacologic inhibition of the DCN1-UBE2M interaction on the NEDD8/CUL pathway.

AB - We previously reported the discovery, validation, and structure-activity relationships of a series of piperidinyl ureas that potently inhibit the DCN1-UBE2M interaction. We demonstrated that compound 7 inhibits both the DCN1-UBE2M protein-protein interaction and DCN1-mediated cullin neddylation in biochemical assays and reduces levels of steady-state cullin neddylation in a squamous carcinoma cell line harboring DCN1 amplification. Although compound 7 exhibits good solubility and permeability, it is rapidly metabolized in microsomal models (CL int = 170 mL/min/kg). This work lays out the discovery of an orally bioavailable analogue, NAcM-OPT (67). Compound 67 retains the favorable biochemical and cellular activity of compound 7 but is significantly more stable both in vitro and in vivo. Compound 67 is orally bioavailable, well tolerated in mice, and currently used to study the effects of acute pharmacologic inhibition of the DCN1-UBE2M interaction on the NEDD8/CUL pathway.

UR - http://www.scopus.com/inward/record.url?scp=85045569727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045569727&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b01282

DO - 10.1021/acs.jmedchem.7b01282

M3 - Article

C2 - 29547693

AN - SCOPUS:85045569727

VL - 61

SP - 2694

EP - 2706

IS - 7

ER -

Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this